MGP
ALNY icon

M&G plc’s Alnylam Pharmaceuticals ALNY Stock Holding History

M&G plc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Sell
35,912
-1,744
-5% -$526K 0.05% 213
2026
Q1 		$12.5M Buy
+37,656
New +$12.8M 0.06% 182

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

M&G plc's ALNY Position: Q2 2026 in Review

M&G plc reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.6% in Q2 2026, selling an estimated $526K and leaving 35,912 shares worth $10.8M. The position accounts for 0.05% of the portfolio, ranked #213.

M&G plc first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $12.5M in Q1 2026. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • M&G plc held 35,912 shares of Alnylam Pharmaceuticals worth $10.8M as of Q2 2026.
  • M&G plc sold 1,744 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $526K.
  • Alnylam Pharmaceuticals made up 0.05% of M&G plc's portfolio in Q2 2026, its #213 holding.
  • M&G plc first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • M&G plc's Alnylam Pharmaceuticals position peaked at $12.5M in Q1 2026.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.